HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Improvement in Visual Fields After Treatment of Intracranial Meningioma With Bevacizumab.

Abstract
High-grade (World Health Organization [WHO] Grade II and III) meningiomas constitute a minority of all meningioma cases but are associated with significant morbidity and mortality, due to more aggressive tumor behavior and a tendency to recur despite standard therapy with resection and radiotherapy. They display a higher degree of vascularity than WHO Grade I meningiomas and produce angiogenic and growth factors, including vascular endothelial growth factor (VEGF). Bevacizumab, a humanized monoclonal antibody against VEGF-A, has been used in the treatment of recurrent or progressive meningiomas resistant to standard therapy. We report a patient with a recurrent left frontotemporal meningioma and associated-vision loss who experienced substantial visual field recovery after 3 cycles of bevacizumab. In addition, we provide a review of the literature regarding the efficacy of bevacizumab in the treatment of recurrent meningiomas.
AuthorsK Ina Ly, Steven R Hamilton, Robert C Rostomily, Jason K Rockhill, Maciej M Mrugala
JournalJournal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society (J Neuroophthalmol) Vol. 35 Issue 4 Pg. 382-6 (Dec 2015) ISSN: 1536-5166 [Electronic] United States
PMID26049681 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Angiogenesis Inhibitors
  • Bevacizumab
Topics
  • Angiogenesis Inhibitors (adverse effects)
  • Bevacizumab (adverse effects)
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Meningeal Neoplasms (diagnosis, drug therapy)
  • Meningioma (diagnosis, drug therapy)
  • Middle Aged
  • Perceptual Disorders (chemically induced)
  • Visual Field Tests
  • Visual Fields (physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: